Health AI Central
Share:
Peer-Reviewed Publication
Sci Rep2025;15(1):10101.March 24, 2025Journal Article

Preparation of robust synthetic control samples and their use in a metatranscriptomic clinical test.

Ryan Toma1,2, Lan Hu3,4, Guru Banavar3,4, Momchilo Vuyisich5,6
1Viome Research Institute, Viome Life Sciences, Inc., Seattle, WA, USA. ryan.toma@viome.com.
2Viome Research Institute, Viome Life Sciences, Inc., New York, NY, USA. ryan.toma@viome.com.
3Viome Research Institute, Viome Life Sciences, Inc., Seattle, WA, USA.
4Viome Research Institute, Viome Life Sciences, Inc., New York, NY, USA.
5Viome Research Institute, Viome Life Sciences, Inc., Seattle, WA, USA. momo@viome.com.
6Viome Research Institute, Viome Life Sciences, Inc., New York, NY, USA. momo@viome.com.
PubMed PMC DOI PDF

Abstract

Metatranscriptomics (MT) has the potential to revolutionize the field of molecular diagnostics. Due to the complexity of MT diagnostic models, positive and negative control materials for specific disease indications can be difficult to obtain. Controls must often be sourced directly from patients. This introduces logistical burdens, assay variability, and limits high throughput clinical laboratory…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.